TICAGRELOR
Ticagrelor blocks adenosine diphosphate (ADP) receptors of subtype P2Y12. Ticagrelor is a medication classified as an antiplatelet agent. It works by preventing the formation of blood clots in the arteries, thereby reducing the risk of heart attacks and strokes.To reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI).
-The recommended dose of ticagrelor is usually 90 mg twice daily, taken with or without food. It is typically initiated with a loading dose and then continued as a maintenance dose. -oral; 60-90 mg twice daily.
History of intracranial haemorrhage, active bleeding, Hypersensitivity.
Paediatric: Safety and efficacy not yet established Pregnancy: Category c. Lactation: Discontinue drug. Elderly: May be used.
Common side effects of ticagrelor include bleeding, dyspnea (shortness of breath), bradycardia (slow heart rate), and dizziness. Less common but serious side effects may include intracranial hemorrhage, gastrointestinal bleeding, and allergic reactions.
Ticagrelor may interact with other medications, including anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain antibiotics. Concurrent use of ticagrelor with these medications may increase the risk of bleeding or other adverse effects.
